Compare CTS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | NRIX |
|---|---|---|
| Founded | 1896 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 2020 |
| Metric | CTS | NRIX |
|---|---|---|
| Price | $52.37 | $15.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $29.46 |
| AVG Volume (30 Days) | 180.3K | ★ 786.8K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 15.87 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $541,318,000.00 | $76,987,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $5.00 | $29.30 |
| P/E Ratio | $24.37 | ★ N/A |
| Revenue Growth | 4.95 | ★ 99.31 |
| 52 Week Low | $34.02 | $8.18 |
| 52 Week High | $59.66 | $22.50 |
| Indicator | CTS | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 43.15 |
| Support Level | $40.41 | $15.22 |
| Resistance Level | $59.66 | $19.98 |
| Average True Range (ATR) | 1.76 | 0.71 |
| MACD | -0.67 | 0.06 |
| Stochastic Oscillator | 9.27 | 36.57 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.